This Domain For Sale – Lee Ann Torrans
- The goal of this website is to raise international awareness of the dangers associated with the birth control pill Yaz.
- Typically, pages are cached in 35 languages. For this reason ample space is required.
- I can no longer do all the work but I can help. Please contact me to purchase this domain.
Bayer Women’s Healthcare encompasses contraceptive products such as yaz® / Yasmin® /Yasminelle® and Mirena®, and hormone replacement therapies such as Angeliq®.
Lee Ann Torrans
ltorrans@gmail.com
FDA Adviser Tied to Bayer
Some FDA advisers are tied to Bayer, the Wall Street Journal reported. Additionally, the Project on Government Oversight outlined the conflict in a letter to the FDA on January 11, 2011.
This conflict occurred at December 8, 2011, hearing in which two FDA advisory committees, the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee met to consider the benefits and risks of the oral contraceptives Yaz and Yasmin and related contraceptives containing the drug drospirenone.
Yaz and Yasmin, manufactured by Bayer HealthCare Pharmaceuticals, Inc. are among the most popular and profitable oral contraceptives in the U.S. An Associated Press article recently stated that “Yaz, Yasmin and related drospirenone-containing pills were Bayer’s second-best-selling franchise last year at $1.6 billion in global sales.”
These same FDA advisers, in a recent vote, said the benefits of four well known Bayer AG (BAYRY) birth control pills outweigh the blood clot risk. What the FDA didn’t reveal is that three of the advisers have had direct ties to Bayer, reports the Wall Street Journal. Reference Link
With sales on the decline in the United States Bayer targets Asian companies according to its publicly filed documents.
Bayer’s Most Recently Filed Reports and Conference Calls
The 2011 Annual Report is anticipated to be out February 28, 2012.
The 2010 Annual Report indicated: “Sales of the Pharmaceuticals segment increased by 4.2% in 2010 to €10,908 million (2009: €10,467 million). Adjusted for currency and portfolio effects, business was up by 0.9%.
Sales grew strongly in the Asia / Pacific and Latin America / Africa / Middle East regions but decreased in North America, mainly because of lower sales of yaz® in the United States. Reforms in the statutory health care systems of various countries also had a negative impact on the business….
Sales of the Women’s Health Care and General Medicine business unit advanced by 4.3% to €6,816million (2009:€6,532million). After adjusting for exchange rates, sales were level with the prior year (+0.0%). There was a distinct drop in sales of the yaz® / Yasmin® / Yasminelle® line of oral contraceptives….
The contraceptives yaz® Plus and Yasmin® Plus, which each contain folate in addition to the hormonal components, were registered in the United States under the trade names Beyaz® and SafyralTM, respectively. Our new oral contraceptive, marketed in Europe since May 2009 under the name Qlaira®, was registered in the United States as NataziaTM in the second quarter of 2010. The additional indication for treatment of heavy and /or prolonged menstrual bleeding was registered in Europe in October and has also been submitted for registration in the United States.
…………….
The Bayer Group currently owns some 78,000 patents or patent applications. Although in our Pharmaceuticals segment the patents on Avalox® / Avelox®, Betaferon® / Betaseron®, Kogenate®, Levitra®, Magnevist®, Mirena®, Nexavar®, Xarelto®, yaz®, Yasmin® and Yasminelle® are particularly important to our business, we believe that no single patent (or group of related patents) is crucial to our business as a whole.
